Bio-Techne Corp

Common Name

Bio-Techne

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

3,100

Ticker

TECH

Exchange

NASDAQ/NGS

Website

www.bio-techne.com

Description

Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing ... Show more

Income Statement Balance Sheet Group Entities

Bio-Techne's Financial Statements Preview

Below are the financial statements of Bio-Techne, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of USD	2025 as of 2025-06-30	2024 as of 2024-06-30
Assets	—	—
Current assets	—	—
Cash and cash equivalents	162.19^a	151.79^a
Short-term available-for-sale investments	0^a	1.07^a
Accounts receivable, less allowances	206.88^a	241.39^a
Inventories	189.45^a	179.73^a
Current assets held-for-sale	12.33^a	9.77^a
Other current assets	37.46^a	33.66^a
Total current assets	608.3^a	617.42^a
Property and equipment, net	245.72^a	251.15^a
Right-of-use assets	73.4^a	91.29^a
Goodwill	980.94^a	972.66^a
Intangible assets, net	365.6^a	507.08^a
Deferred tax asset	10.31^a	0^a
Other assets	273.61^a	264.27^a
Total assets	2,557.87^a	2,703.87^a
Liabilities and shareholders’ equity	—	—
Current liabilities	—	—
Trade accounts payable	25.31^a	37.97^a
Salaries, wages and related accruals	65.79^a	49.82^a
Accrued expenses	25.66^a	24.89^a
Contract liabilities	32.57^a	27.93^a
Income taxes payable	10.77^a	3.71^a
Operating lease liabilities - current	14.1^a	12.92^a
Other current liabilities	1.65^a	2.15^a
Total current liabilities	175.85^a	159.38^a
Deferred income taxes	6.17^a	55.86^a
Long-term debt obligations	346^a	319^a
Operating lease liabilities	83.96^a	87.62^a
Other long-term liabilities	27.08^a	13.16^a
Shareholders’ equity	—	—
Undesignated capital stock	0^a	0^a
Common stock	1.55^a	1.58^a
Additional paid-in capital	911.09^a	820.34^a
Retained earnings	1,066.05^a	1,325.25^a
Accumulated other comprehensive loss	-59.88^a	-78.32^a
Total shareholders’ equity	1,918.81^a	2,068.85^a
Total liabilities and shareholders’ equity	2,557.87^a	2,703.87^a

Download Data

Verified Sources Behind Bio-Techne’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Bio-Techne’s data sources below and access millions more through our Disclosure Search.

a. Bio-Techne's 10-K 2025

b. Bio-Techne's Annual Report 2025

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Bio-Techne Corp

Bio-Techne's Financial Statements Preview

Verified Sources Behind Bio-Techne’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

BioMarin Pharmaceutical Inc

Royalty Pharma PLC

Moderna Inc

Madrigal Pharmaceuticals Inc

BridgeBio Pharma Inc

Cytokinetics Inc